Daily Endocrinology Research Analysis
Three impactful endocrinology/metabolism studies span mechanism, precision risk, and therapy: (1) colonic inflammation drives adaptive pancreatic β-cell proliferation via a liver–nerve–pancreas axis, (2) genetic risk (especially PNPLA3) predicts decade-wise fibrosis progression in MASLD, and (3) a randomized trial shows pioglitazone plus empagliflozin synergistically reduces liver fat and stiffness in T2D with MASLD.
Summary
Three impactful endocrinology/metabolism studies span mechanism, precision risk, and therapy: (1) colonic inflammation drives adaptive pancreatic β-cell proliferation via a liver–nerve–pancreas axis, (2) genetic risk (especially PNPLA3) predicts decade-wise fibrosis progression in MASLD, and (3) a randomized trial shows pioglitazone plus empagliflozin synergistically reduces liver fat and stiffness in T2D with MASLD.
Research Themes
- Gut–liver–pancreas cross-talk regulating β-cell adaptation
- Genetic risk stratification for fibrosis progression in MASLD
- Combination therapy for MASLD in type 2 diabetes
Selected Articles
1. Colonic inflammation triggers β cell proliferation during obesity development via a liver-to-pancreas interorgan mechanism.
In mouse models, colonic inflammation induced by DSS or high-fat diet activates hepatic ERK and a splanchnic–vagal neuronal relay to drive adaptive pancreatic β-cell proliferation. Blocking the neuronal pathway or inhibiting gut homing via anti-LPAM1 suppressed β-cell proliferation and hepatic ERK activation. The study identifies a gut-origin signal that tunes β-cell mass during obesity.
Impact: This work uncovers a previously unrecognized gut–liver–pancreas axis that links intestinal inflammation to β-cell mass expansion, redefining β-cell adaptive biology in obesity.
Clinical Implications: Targeting colonic inflammation or the hepatic ERK–autonomic relay could become strategies to modulate β-cell adaptation in insulin resistance, potentially delaying hyperglycemia onset.
Key Findings
- DSS-induced colonic inflammation increased hepatic ERK activation and pancreatic β-cell proliferation; both were suppressed by blocking the neuronal relay.
- Anti-LPAM1 antibody reduced DSS-induced β-cell proliferation, implicating gut homing in the signaling pathway.
- High-fat diet elicited colonic inflammation; anti-LPAM1 suppressed hepatic ERK activation and β-cell proliferation under HFD.
Methodological Strengths
- Multiple in vivo models (DSS colitis and HFD) with convergent results
- Causal interrogation via neuronal relay blockade and anti-LPAM1 intervention
Limitations
- Findings are in animal models; human validation is lacking
- Specific sensory and effector neural components beyond splanchnic/vagal pathways were not fully dissected
Future Directions: Validate the gut–liver–pancreas axis in humans (biomarkers, imaging, neuromodulation), and test whether modulating colonic inflammation alters β-cell mass/function in metabolic disease.
Under insulin-resistant conditions, such as obesity, pancreatic β cells adaptively proliferate and secrete more insulin to prevent blood glucose elevation. We previously reported hepatic ERK activation during obesity development to stimulate a neuronal relay system, consisting of afferent splanchnic nerves from the liver and efferent vagal nerves to the pancreas, thereby triggering adaptive β cell proliferation. However, the mechanism linking obesity with the interorgan system originating in hepatic ERK activation remains unclear. Herein, we clarified that colonic inflammation promotes β cell proliferation through this interorgan system from the liver to the pancreas. First, dextran sodium sulfate (DSS) treatment induced colonic inflammation and hepatic ERK activation as well as β cell proliferation, all of which were suppressed by blockades of the neuronal relay system by several approaches. In addition, treatment with anti-lymphocyte Peyer's patch adhesion molecule-1 (anti-LPAM1) antibody suppressed β cell proliferation induced by DSS treatment. Importantly, high-fat diet (HFD) feeding also elicited colonic inflammation, and its inhibition by anti-LPAM1 antibody administration suppressed hepatic ERK activation and β cell proliferation induced by HFD. Thus, colonic inflammation triggers adaptive β cell proliferation via the interorgan mechanism originating in hepatic ERK activation. The present study revealed a potentially novel role of the gastrointestinal tract in the maintenance of β cell regulation.
2. High inherited risk predicts age-associated increases in fibrosis in patients with MASLD.
In 570 adults with MASLD, high genetic risk (PNPLA3 risk alleles minus HSD17B13 protection) predicted higher decade-wise increases in liver stiffness by MRE, with PNPLA3 G/G showing early divergence by age ~44. Findings were consistent using PRS-HFC/PRS-5 and validated in an external Latin American cohort.
Impact: Provides actionable precision-medicine evidence to incorporate genotype-based risk stratification into MASLD monitoring strategies.
Clinical Implications: Genotyping (e.g., PNPLA3 and HSD17B13) can identify patients likely to experience faster fibrosis progression and who may benefit from earlier, more frequent noninvasive fibrosis assessment and targeted interventions.
Key Findings
- High genetic risk score predicted increased liver stiffness per decade (β=0.28 kPa/10 years; p=0.001), not seen in low-risk patients.
- PNPLA3 C/G and G/G genotypes independently associated with higher LSM; G/G diverged by age ~44; validated externally.
- PRS-HFC and PRS-5 analyses corroborated genetic risk–fibrosis progression associations.
Methodological Strengths
- Integration of MRE with targeted genotyping and polygenic risk scores
- External validation cohort confirming generalizability
Limitations
- Cross-sectional design limits causal inference about fibrosis progression
- Cohort age range (18–70) and demographics may limit applicability to other populations
Future Directions: Prospective longitudinal studies testing genotype-guided surveillance intervals and therapeutic selection; evaluation of combined clinical-genetic risk algorithms.
BACKGROUND & AIMS: Limited data have prevented routine genetic testing from being integrated into clinical practice in metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to quantify the effect of genetic variants on changes in fibrosis severity per decade in patients with MASLD. METHODS: This cross-sectional study included prospectively recruited adults with MASLD aged 18-70 who underwent magnetic resonance elastography (MRE) and genotyping for PNPLA3, TM6SF2, MBOAT7, GCKR, and HSD17B13. A genetic risk score (GRS) was calculated as the sum of established risk alleles in PNPLA3 minus protective variants in HSD17B13 (0 = low risk, 1 = high risk). We also estimated the polygenic risk score-hepatic fat content (PRS-HFC) and the adjusted version (PRS-5). The primary endpoint was the age-related change in liver stiffness measurement (LSM) on MRE by GRS. Findings were validated using an external cohort from Latin America. RESULTS: Among 570 participants, the median age was 57 [49-64] years, 56.8% were women, and 34.2% were Hispanic. Median MRE was 2.4 [2.1-3.0] kPa, and 51% had a high GRS. In the high GRS group, LSM increased per 10-year age increase (β = 0.28 kPa, 95% CI 0.12-0.44, p = 0.001), while no such difference was observed in the low GRS group. Similar findings were observed using PRS-HFC and PRS-5. PNPLA3 genotype alone also predicted higher LSM (C/G: β = 0.32 kPa, 95% CI 0.02-0.61, p = 0.034; G/G: β = 0.87 kPa, 95% CI 0.52-1.22, p <0.0001) and the G/G genotype was associated with a significantly higher LSM by age 44, which was consistent in the validation population. CONCLUSION: GRS, PRS-HFC, PRS-5, and PNPLA3 genotypes alone are associated with increased fibrosis severity per decade, resulting in divergent disease trajectories starting in midlife. Assessing genetic risk in MASLD will identify high-risk patients who require more frequent monitoring. IMPACT AND IMPLICATIONS: This study provides granular evidence that genetic predisposition, particularly the PNPLA3 G/G genotype, significantly influences the trajectory of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), with a more pronounced impact emerging after the fourth decade of life. These findings highlight the importance of incorporating genetic risk assessment into MASLD management, as it allows for the early identification of high-risk individuals who may benefit from more frequent monitoring and targeted interventions. Given the rising global burden of MASLD, clinicians, researchers, and policymakers should consider integrating genetic stratification into existing risk assessment frameworks to refine screening and surveillance strategies. By optimizing patient selection for non-invasive fibrosis assessment and potential therapeutic interventions, this approach could enhance precision medicine efforts and may improve long-term outcomes.
3. Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial.
In a 24-week, open-label RCT (n=50), pioglitazone+empagliflozin achieved the largest reductions in MRI-PDFF and MRE stiffness versus monotherapies in T2D with MASLD. All combination-group participants met ≥30% relative or ≥5% absolute liver fat reduction; half met both ≥30% fat and ≥20% stiffness reduction.
Impact: Demonstrates a plausible, synergistic pharmacologic strategy to treat MASLD in T2D using readily available agents, with quantitative MRI endpoints.
Clinical Implications: In T2D with MASLD, combining a TZD (pioglitazone) and an SGLT2 inhibitor (empagliflozin) may better reduce hepatic steatosis and stiffness than either alone, while favorably impacting visceral adiposity and adiponectin.
Key Findings
- Combination therapy produced the greatest reductions in MRI-PDFF and MRE stiffness over 24 weeks.
- 100% of the combination group achieved ≥30% relative or ≥5% absolute liver fat reduction (vs 57.1% PIO, 87.5% EMPA; p=0.010).
- 50% of the combination group achieved ≥30% liver fat and ≥20% stiffness reduction (vs 21.4% PIO, 6.3% EMPA; p=0.029).
- Combination reduced visceral fat the most and increased adiponectin the most, without the subcutaneous fat changes seen with monotherapy.
Methodological Strengths
- Randomized allocation with quantitative MRI-PDFF and MRE endpoints
- Registered trial (NCT03646292) with objective imaging-based outcomes
Limitations
- Open-label design with small sample size (n=50) and 24-week duration
- Single-center and dosing fixed; not powered for clinical events
Future Directions: Confirm efficacy and safety in larger, blinded, multicenter RCTs with histologic endpoints; explore dose optimization and class-generalizability.
BACKGROUND: The close interplay between metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes supports the need to identify beneficial combination therapies of antidiabetic medications targeted for the treatment of MASLD. This study aimed to investigate the complementary effects of combination therapy with pioglitazone (PIO) and empagliflozin (EMPA) on MASLD in individuals with type 2 diabetes. METHODS: In a randomized, open-label trial, 50 participants with type 2 diabetes and MASLD were assigned 1:1:1 to receive PIO 15 mg, EMPA 10 mg, or a combination (PIO 15 mg plus EMPA 10 mg) daily for 24 weeks. Liver fat fraction and stiffness were evaluated using magnetic resonance imaging-proton density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE), respectively. RESULTS: Combination therapy resulted in the largest reduction in liver fat and stiffness among treatment groups. Participants experiencing a relative reduction ≥ 30% or an absolute reduction ≥ 5% in liver fat were the most prevalent in the combination group (100.0% vs. 57.1% in PIO and 87.5% in EMPA, p = 0.010). In addition, the combination group showed the highest proportion of individuals with a relative reduction ≥ 30% in liver fat and ≥ 20% in liver stiffness than the monotherapy groups (50.0% vs. 21.4% in PIO and 6.3% in EMPA, p = 0.029). Combination therapy did not induce the changes in subcutaneous fat deposition observed in the monotherapy groups, but it did show the most substantial reduction in visceral fat, concurrently showing the largest increase in adiponectin level across the three groups (p = 0.036). CONCLUSIONS: Combination therapy of PIO with EMPA showed synergistic benefits for MASLD in individuals with type 2 diabetes, compensating for the inadequate or unfavorable effects of monotherapies; ClincialTrials.gov number, NCT03646292. TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov (registration number: NCT03646292).